deCODE genetics (Nasdaq:DCGN) today announced that
Dr. Hakon Hakonarson, who has served with diligence
in various positions at deCODE over the past eight
years, most recently as Vice President of Business
Development, is leaving the company to pursue other
interests. The company wishes him all the best in his
new endeavors. Tomas Sigurdsson, deCODE’s Vice President,
Treasury and New Alliances, will assume responsibility
for the company’s business development.
About deCODE
deCODE genetics (NASDAQ:DCGN) is a global leader in
applying human genetics to develop drugs for common
diseases. Our population approach has enabled us
to discover and target key biological pathways involved
in conditions ranging from heart attack to cancer.
We are turning these discoveries into new medicine
to better treat and prevent many of the biggest challenges
to public health. deCODE is delivering on the promise
of the new genetics.SM Visit us on the web at www.decode.com.
Any statements contained in this presentation that
relate to future plans, events or performance are forward-looking
statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These forward-looking
statements are subject to a number of risks and uncertainties
that could cause actual results to differ materially
from those described in the forward-looking statements.
These risks and uncertainties include, among others,
those relating to technology and product development,
integration of acquired businesses, market acceptance,
government regulation and regulatory approval processes,
intellectual property rights and litigation, dependence
on collaborative relationships, ability to obtain financing,
competitive products, industry trends and other risks
identified in deCODE’s filings with the Securities
and Exchange Commission. deCODE undertakes no obligation
to update or alter these forward-looking statements
as a result of new information, future events or otherwise.
